Inovio Pharmaceuticals (NASDAQ:INO) Issues Quarterly Earnings Results

Inovio Pharmaceuticals (NASDAQ:INO) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07, Zacks reports.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO opened at $2.04 on Wednesday. Inovio Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $5.26. The company has a market cap of $108.15 million, a price-to-earnings ratio of -0.78 and a beta of 1.64. The business’s 50 day moving average price is $2.43 and its 200-day moving average price is $2.05.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Inovio Pharmaceuticals by 35.0% during the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock worth $6,348,000 after acquiring an additional 703,727 shares during the period. Qube Research & Technologies Ltd purchased a new position in Inovio Pharmaceuticals during the 2nd quarter worth $234,000. AQR Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the 1st quarter valued at $120,000. JPMorgan Chase & Co. lifted its holdings in shares of Inovio Pharmaceuticals by 1,667.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 61,516 shares during the period. Finally, Jane Street Group LLC grew its position in shares of Inovio Pharmaceuticals by 221.2% during the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 27,329 shares in the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

INO has been the subject of a number of analyst reports. Wall Street Zen lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. HC Wainwright reaffirmed a “neutral” rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a report on Thursday, August 14th. Zacks Research cut Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Citigroup reissued a “market outperform” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Inovio Pharmaceuticals in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.80.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.